search
Back to results

Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma (#9105)

Primary Purpose

Bronchiolitis

Status
Completed
Phase
Phase 1
Locations
Qatar
Study Type
Interventional
Intervention
Dexamethasone
Placebo
Sponsored by
Hamad Medical Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bronchiolitis focused on measuring Dexamethasone, Bronchiolitis

Eligibility Criteria

4 Weeks - 18 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Infant's ≥ 4weeks and ≤ 18 month.
  • First time wheezers.
  • Bronchiolitis clinical severity score ≥ 4.
  • History of eczema in the patient.
  • Parenteral history of asthma
  • Sibling history of asthma

Exclusion Criteria:

  • Prematurity (Gestational age 34 weeks or less).
  • Previous history of wheezing episode.
  • Use of steroids within the last 48 hours.
  • Critically ill patients with one or more of the following:

    • Obtunded consciousness,
    • Progressive respiratory failure requiring PICU admission.
    • History of apnea.
    • Oxygen saturation less than 85%.
  • Chronic lung disease of prematurity.
  • Cystic fibrosis.
  • Congenital heart disease.
  • Immunodeficiency.
  • Exposure to Varicella within 21 days before enrollment.

Sites / Locations

  • Hamad Medical Corporation, Pediatric Emergency Center,Alsaad.

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Ventolin - Dexamethasone group

Ventolin - Placebo group

Arm Description

Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.

Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.

Outcomes

Primary Outcome Measures

Patients diagnosed as bronchiolitis were discharged at 12 hours for each group

Secondary Outcome Measures

Patients diagnosed as bronchiolitis were discharged at 18, 24 , 36 and 48 hours for each group

Full Information

First Posted
January 12, 2010
Last Updated
August 9, 2016
Sponsor
Hamad Medical Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT01065272
Brief Title
Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma
Acronym
#9105
Official Title
Dexamethasone Versus Placebo in the Treatment of Viral Bronchiolitis in Patients With Either Eczema and or Parental or Sibling History of Asthma.A Randomized Controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
August 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hamad Medical Corporation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators hypothesized that oral Dexamethasone in addition to nebulized Salbutamol will improve the Bronchiolitis Clinical Severity Score,duration of treatment in the short stay unit,need for hospitalization and readmissions to the pediatric emergency in a subgroup of patients diagnosed as Bronchiolitis with either eczema and or a parental or sibling history of Asthma. Two groups randomized will be given Nebulized Ventolin plus either oral Dexamethasone or placebo for 5 days. Bronchiolitis severity score plus vital signs will be recorded regularly until patient is fit for discharge. Patients will be discharged on Ventolin inhaler and to complete the five days course of oral Dexamethasone Patients will be followed up for 7 days post discharge by telephone.
Detailed Description
This is a prospective, randomized, double blinded controlled study. It will be conducted in the main Pediatric Emergency Centre in Qatar(Al- Saad),during the period of Jan 2010 - April 2012. The study has been approval by the Institution Research Board. The sample size will be 200 patients.100 patients in each arm. Patients triaged as moderate to severe bronchiolitis will be evaluated and eligible patients are admitted to short stay unit and managed as usual. History and full physical examination will be done by the attending physician and the nurse will check 02 sat., respiratory rate and pulse rate. The Bronchiolitis clinical severity score will be assessed and then guardians of eligible patients will be approached explaining the purpose and treatment modalities. Patients will be included after obtaining a verbal and written consent. A CXR and an RSV test will be done for all study patients upon recruitment. The attending physician will complete the data collection sheet A computer generated randomization code will be prepared by the statistician. A pharmacist will prepare the study medications and the placebo. Patients will be randomized to either one of the two treatments:- Ventolin-Dexamethasone group: Oral Dexamethasone 1mg/kg will be given for the first day and then 0.6mg/kg for the next 4 days in addition to the Ventolin nebulizations. Ventolin-Placebo group: Oral Placebo with a volume equivalent to that of Dexamethasone will be given for the first day and then for the next 4 days in addition to the Ventolin nebulizations. Nebulized Ventolin 0.5ml in 2 ml Normal Saline will also be given at 0, 30, 60, 120 and 180 minutes and then every 2hours. Bronchiolitis severity score and O2 saturation will be recorded at enrollment, then after 4,6 and 12hours then every 12 hourly until discharged. To give additional Ventolin nebulization will be decided clinically as per the discretion of the treating physician and will be recorded. Nebulized epinephrine will not be used except if the patient is severely distressed. Nebulized Epinephrine 0.5 mg/kg (max 5mg/dose) mixed in 3ml normal saline will be allowed for severely distressed patients as an add on therapy given on PRN basis.. Additional interventions such as Oxygen therapy, Intravenous fluids and PRN nebulized Epinephrine will be recorded as additional therapies. Patients fit for discharge will have their nebulization stopped & date, time documented. Physician will discharge patients based on clinical grounds as not needing supplemental oxygen,minimal or no chest recessions,minimal wheezing or crackles and feeding adequately Patients will be sent home on Ventolin inhaler 2 puffs q 4 hours for 48 hours Then 2 puffs every 4 hours when needed plus the study medication syrup to complete 5days course. Follow up for one-week post discharge by a phone call daily will be conducted and patients will be assessed in PEC when needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchiolitis
Keywords
Dexamethasone, Bronchiolitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ventolin - Dexamethasone group
Arm Type
Active Comparator
Arm Description
Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
Arm Title
Ventolin - Placebo group
Arm Type
Placebo Comparator
Arm Description
Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
Steroids
Intervention Description
0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge. 1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
normal saline plus cherry flavour
Intervention Description
0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge. 1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days
Primary Outcome Measure Information:
Title
Patients diagnosed as bronchiolitis were discharged at 12 hours for each group
Time Frame
12 hours
Secondary Outcome Measure Information:
Title
Patients diagnosed as bronchiolitis were discharged at 18, 24 , 36 and 48 hours for each group
Time Frame
48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Weeks
Maximum Age & Unit of Time
18 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Infant's ≥ 4weeks and ≤ 18 month. First time wheezers. Bronchiolitis clinical severity score ≥ 4. History of eczema in the patient. Parenteral history of asthma Sibling history of asthma Exclusion Criteria: Prematurity (Gestational age 34 weeks or less). Previous history of wheezing episode. Use of steroids within the last 48 hours. Critically ill patients with one or more of the following: Obtunded consciousness, Progressive respiratory failure requiring PICU admission. History of apnea. Oxygen saturation less than 85%. Chronic lung disease of prematurity. Cystic fibrosis. Congenital heart disease. Immunodeficiency. Exposure to Varicella within 21 days before enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Khalid M Al-Ansari, FRCPC,FAAP
Organizational Affiliation
Hamad Medical Corporation, Weill Cornell Medical College, Doha-Qatar
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamad Medical Corporation, Pediatric Emergency Center,Alsaad.
City
Doha
ZIP/Postal Code
3050
Country
Qatar

12. IPD Sharing Statement

Learn more about this trial

Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma

We'll reach out to this number within 24 hrs